Class 1A PI3K regulates vessel integrity during development and tumorigenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 28, 2008, Pages 9739-9744

  Yuan, Tina L ^a,b   Choi, Hak Soo ^b   Matsui, Aya ^b   Benes, Cyril ^b   Lifshits, Eugene ^c   Luo, Ji ^a   Frangioni, John V ^b   Cantley, Lewis C ^a,b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d NRB 1030 ^*  (United States)

Author keywords

Angiogenesis; Endothelium; Neovasculature

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P50; PROTEIN P55; PROTEIN P85; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLEEDING; CARCINOGENESIS; CELL LOSS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE DELETION; HETEROZYGOSITY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SURVIVAL; TUMOR CELL; TUMOR VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOOD VESSELS; CAPILLARY PERMEABILITY; ENDOTHELIUM, VASCULAR; HETEROZYGOTE; MICE; MICE, MUTANT STRAINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEIN SUBUNITS;

MUS;

EID: 47749118003     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804123105     Document Type: Article

References (37)

1. Samuels Y et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554.
2. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988-1004.
3. Carpten JD et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439-444.
4. Huang CH et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857):1744-1748.
5. Miled N et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835):239-242.
6. Isakoff SJ et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992-11000.
7. Samuels Y et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-573.
8. Knight ZA, Shokat KM (2007) Chemically targeting the PI3K family. Biochem Soc Trans 35(Pt 2):245-249.
9. Ward SG, Finan P (2003) Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3(4):426-434.
10. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273-286.
11. Fidler JJ (2003) The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3(6):453-458.
12. Hofer E, Schweighofer B (2007) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97(3):355-363.
13. Cantley LC (2002) The Phosphoinositide 3-Kinase Pathway. Science 296(5573):1655-1657.
14. Engelman JA et al (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102(10):3788-3793.
15. Engelman JA et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043.
16. Chen J et al (2005) Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 11(11):1188-1196.
17. Phung TL et al (2006) Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10(2):159-170.
18. Tothova Z et al (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128(2):325-339.
19. Hamada K et al (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19(17):2054-2065.
20. Johannessen CM et al (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18(1):56-62.
21. Phung TL et al (2007) Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 67(11):5070-5075.
22. Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103(5):1475-1479.
23. Ueki K et al (2002) Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99(1):419-424.
24. Luo J et al (2005) Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25(21):9491-9502.
25. Schlaeger TM (1997) Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 94(7):3058-3063.
26. Mao X, Fujiwara Y, Chapdelaine A, Yang H, Orkin SH (2001) Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 97(1):324-326.
27. Yu J et al (1998) Regulation of the p85/p110 phosphatidylinositol 3′-kinase: Stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18(3):1379-1387.
28. Drake CJ, Fleming PA (2000) Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 95(5):1671-1679.
29. Jones EA, Baron MH, Fraser SE, Dickinson ME (2004) Measuring hemodynamic changes during mammalian development. Am J Physiol Heart Circ Physiol 287(4):H1561-9.
30. Brachmann SM et al (2005) Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol h 25(7):2593-2606.
31. Furuyama T et al (2004) Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279(33):34741-34749.
32. Sun JF et al (2005) Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 102(1):128-133.
33. Schnell CR et al (2008) Effects of the dual pan-class I PI3K/mTOR inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Manuscript under review.
34. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
35. Martin-Belmonte F, Mostov K (2008) Regulation of cell polarity during epithelial morphogenesis. Curr Opin Cell Biol 20(2):227-234.
36. Kölsch V, Charest PG, Firtel RA (2008) The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci 121(Pt 5):551-559.
37. Hoang MV, Senger DR (2005) In vivo and in vitro models of Mammalian angiogenesis. Methods Mol Biol 294:269-285.